Navigation Links
Multiple Sclerosis drug, Tysabri banned due to neurological disorders

Tysabri, which is used in the treatment of Multiple Sclerosis (MS), has been withdrawn from market after the two patients taking the drug complained of neurological disorders. The relationship between the drug and // Progressive Multifocal Leukoencephalopathy (PML) is being researched by the scientists. If the drug is deemed to pose a significant risk, it could be a serious setback for the entire class of drugs, which work by blocking passage of immune cells in to the brain.

“Other cell migration inhibitors in development will have to be carefully tested, says Howard Weiner, director of the partners MS center at Brigham and Women’s Hospital. Several companies are developing drugs that use the same compounds to treat Crohn disease, rheumatoid arthritis and asthma. The US FDA has halted a phase 2 trial of a GlaxoSmithKline drug that targets the same protein, alpha-4 integrin, as Tysabri. Australian biotech Antisense Therapuetics stopped Phase 2 trial in March for similar MS drugs, which the company had also planned to develop as an asthma treatment. The FDA in November 2004 granted Tysabri fast track approval, after initial phase 3 results attacks by as much as 66%. Tysabri was expected to be a major blockbuster for its manufacturer Biogen Idec, but the company suspended sales of Tysabri in February, after learning of the two PML cases, one of which was fatal. The company also halted trials of the drug for rheumatoid arthritis and Crohn disease.

There has never previously been a documented case of PML in MS patients, even though these patients have been treated with many types of immunosuppresants. Both patients diagnosed with PML had taken Tysabri with Avonex, another MS drug, for two years n clinical trials.

Source: Nature Medicie
'"/>




Page: 1

Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Multiple organ disease cured by genes
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. Life Quality For Patients With Multiple Sclerosis
5. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
6. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
7. Hope For Patients With Multiple Sclerosis
8. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
9. Debating The Link Between Sex Hormones And Multiple Sclerosis
10. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
11. Decreasing Multiple Births By Single Embryo Transfers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... the alternative health care industry, announces Chris Brandl as its New Guest Director. ... vision and purpose to corporations throughout his career. He began his professional career ...
(Date:2/27/2017)... , ... February 27, 2017 , ... Much attention has ... for women who become dependent on opioid painkillers has fallen short. From 1999 until ... to a 237% increase in fatal overdoses in male populations.(1) , The proportion of ...
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... Periodontitis is a chronic inflammatory gum condition that occurs when the bacteria in plaque ... cleaning, also referred to as a scaling and root planing or SRP, and can ...
(Date:2/27/2017)... ... , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and ... for Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss ... compiled into a single volume a compelling argument that the disease does exist in ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley ... to announce a new informational post on robotic hair transplantation. San Francisco residents ... hair transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... -- This report provides all the information you require ... activities since 2010. Download the full report: ... and Alliance since 2010 report provides an in-depth insight ... leading life sciences companies. On demand company ... the most up to date deal and company data. ...
(Date:2/28/2017)... Feb. 27, 2017 This report provides all ... its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... , Feb 28, 2017 Research ... Enzyme Supplements Market Forecasts 2014-2025" report to their offering. ... ... USD 1.6 billion by 2025. Growing consumer awareness regarding the ... health is expected to stimulate industry growth over the forecast ...
Breaking Medicine Technology: